Cendakimab

Cendakimab, under development for eosinophilic esophagitis and gastroenteritis, is expected to generate $143 mn in annual revenue by 2037 in the US. Bristol-Myers Squibb, a biopharmaceutical company, reported revenues of $45,006 mn for FY2023, with a net margin of 17.8%.

October 2024 saw significant gastroenterology news, including FDA approval of Exact Sciences’ Cologuard Plus test for colorectal cancer screening, and research from the ACG 2024 meeting on cendakimab for eosinophilic esophagitis, vitamin D deficiency in IBD outcomes, and long-term mirikizumab efficacy in ulcerative colitis and Crohn’s disease. GLP-1 RA use was linked to increased food retention and poor bowel preparation in endoscopy, but not to significant medical risks. Depression symptoms were found to negatively impact dietary intervention response in IBS patients, while stress was identified as a major trigger for IBS symptoms.

Cendakimab demonstrated durable safety and efficacy in treating eosinophilic esophagitis (EoE) in a phase 3 study, showing significant improvements in symptoms and esophageal eosinophils through 48 weeks versus placebo. Presented at the ACG 2024 Annual Scientific Meeting, the study enrolled 430 patients and highlighted cendakimab's potential as a promising therapy for EoE.